ClinicalTrials.gg
CompletedNCT02750943Updated Oct 26, 2017Results posted

Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease

An interventional study of Stannous Fluoride and Sodium Monofluorophosphate in Gingivitis, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-26.

Sponsored by GlaxoSmithKline · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
253
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing Tin Fluorides in Gingivitis — 1 open to participants now, 3 under way, none of them phase 3. Tin Fluorides · Gingivitis.

Enrollment
3rd of 23
253 · median 115
Started
2015
with 2 others
No phase
10 of 23
none open now
Registered
7th of 23
by date
Lead sponsor
2 of 23
GlaxoSmithKline

Among the 23 studies testing Tin Fluorides in Gingivitis, this one is the 3rd largest by enrollment, is one of 3 that started in 2015, is one of 10 with no phase, and was the 7th registered.

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

Browse Gingivitis studies →

Open to participants now

1 of the 23 studies testing Tin Fluorides in Gingivitis is open now. Recruiting first, the newest first:

About Tin Fluorides

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing Tin Fluorides in Gingivitis, or all of them as a file.
02

Study summary

This will be a single-center, 12 week, examiner-blind, randomized, stratified (gender and baseline mean whole mouth MGI score), two-treatment, parallel group, clinical study in healthy adult volunteers with moderate gingivitis. This study will evaluate the efficacy of a dentifrice containing 0.454% weight by weight (w/w) stannous fluoride to control gingivitis and gingival bleeding following 12 weeks twice daily brushing, compared to a negative control dentifrice.

03

Conditions studied

  • Gingivitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written and has received a signed and dated copy of the informed consent form.
  • Good general health with (in the opinion of the investigator) no and relevant abnormalities of medical history or oral/dental examination.
  • Absence of any condition that would impact on the subject's safety or wellbeing or affect the individual's ability to understand and follow study procedures and requirements.
  • A minimum of 20 permanent gradable teeth. (Gradable teeth are those where restorative materials cover less than 25% of the tooth surface graded).
  • Moderate gingivitis present at the screening visit in the opinion of the investigator from a gross visual gingival assessment.
  • Visible blood in toothpaste expectorant at Screening and Baseline (Visit 2).

Exclusion criteria

Exclusion Criteria:

  • Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
  • Women who are breast-feeding
  • Known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • Participation in another clinical study (including cosmetic studies) or receipt of an drug within 30 days of the screening visit.
  • Previous participation in this study.
  • Recent history (within the last year) of alcohol or other substance abuse.
  • An employee of the sponsor or the study site or members of their immediate family.
  • An employee of any toothpaste manufacturer or their immediate family.
  • Medical History/Current Medication A. Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any other medical condition (e.g. Diabetes Mellitus) that would make the subject unlikely to fully complete the study or any that increases the risk to the subject or undermines the data validity B.Screening i. Currently taking antibiotics or requiring antibiotic use prior to dental prophylaxis or other dental procedures.

ii. Currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.

iii. Currently taking a systemic medication which, in the opinion of the C. Baseline, Day 28 and Day 96 Assessment Visits i. Has taken antibiotics in the previous 14 days. ii. Has taken an anti-inflammatory medication which, in the opinion of the investigator, could affect gingival condition in the previous 14 days.

iii. Has taken a systemic medication which, in the opinion of the investigator, could affect gingival condition in the previous 14 days (e.g. calcium channel blockers, or aspirin therapy).could affect gingival condition in the previous 14 days (e.g. calcium channel blockers, or aspirin therapy).Investigator, could affect gingival condition (e.g. calcium channel blockers, or aspirin therapy).

  • Have current active caries or periodontitis that may, in the opinion of the investigator, compromise the study or the oral health of the subjects if they participate in the study.
  • Restorations in a poor state of repair.
  • Partial dentures or orthodontic appliances.
  • Teeth bleaching within 12 weeks of screening.
  • Use of a chlorhexidine mouthwash within 14 days of baseline.
  • Current smokers or smokers who have quit within the past 6 months prior to screening or subjects currently using smokeless forms of tobacco, e.g. Gutkha, Pan containing tobacco, Pan Masala or nicotine based e-cigarettes.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
253 participants (actual)

Study arms

  • Experimental
    Stannous Fluoride

    Participants will apply a full ribbon of dentifrice containing 0.454% w/w stannous fluoride to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)

    Drug: Stannous Fluoride

  • Active comparator
    Sodium Monofluorophosphate

    Participants will apply a full ribbon of dentifrice containing Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)

    Drug: Sodium Monofluorophosphate

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Bleeding Sites at Week 12

    Number of bleeding sites was measured as bleeding index (BI) via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth (7-7 in each arch). The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. Bleeding sites were assessed as the number of bleeding sites with a BI score of 1 or 2.

    Time frame: Week 12

Secondary outcomes

  1. Number of Bleeding Sites at Week 4

    Number of bleeding sites was measured as BI via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth (7-7 in each arch). The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. Bleeding sites were assessed as the number of bleeding sites with a BI score of 1 or 2.

    Time frame: Week 4

  2. Bleeding Index (BI) at Week 4 and Week 12

    BI was assessed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system to be used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed

    Time frame: Week 4, Week 12

  3. Modified Gingival Index (MGI) at Week 4 and Week 12

    MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration.

    Time frame: Week 4, Week 12

  4. Number of Participants With Visible Blood in Expectorate (Presence [Trace, Substantial]/Absence) at Week4 and Week 12

    Visible blood in expectorate for each participant was classified as (i) Present (Trace or Substantial) (ii) Absent. The number of participants with blood 'Present' (Trace or Substantial) or 'absent' in expectorate was analyzed.

    Time frame: Week 4, Week 12

07

Results

Posted Nov 11, 2016

Participant flow

Participants were recruited in a single center in Germany.

Participant flow — Overall Study
MilestoneStannous FluorideSodium Monofluorophosphate
Started125128
Completed119119
Not completed69
Withdrew: Lost to follow-up12
Withdrew: Withdrawal by subject57

Outcome measures

PrimaryNumber of Bleeding Sites at Week 12

Number of bleeding sites was measured as bleeding index (BI) via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth (7-7 in each arch). The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. Bleeding sites were assessed as the number of bleeding sites with a BI score of 1 or 2.

Time frame:
Week 12
Reported as:
Least squares mean · number of bleeding sites
Number of Bleeding Sites at Week 12
number of bleeding sitesStannous FluorideSodium Monofluorophosphate
Number of Bleeding Sites at Week 1242.02 ± 1.9167.36 ± 1.91
Statistical analysis
  • Stannous Fluoride vs Sodium Monofluorophosphate · ANCOVA · p = <0.0001 (From ANCOVA analysis with treatment group, gender and baseline MGI stratification as factors baseline as covariates.) · Least square (ls) mean difference: -25.340 · 95% CI -30.682 to -19.998Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
SecondaryNumber of Bleeding Sites at Week 4

Number of bleeding sites was measured as BI via a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth (7-7 in each arch). The BI scoring system used to measure bleeding sites is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed. Bleeding sites were assessed as the number of bleeding sites with a BI score of 1 or 2.

Time frame:
Week 4
Reported as:
Least squares mean · number of bleeding sites
Number of Bleeding Sites at Week 4
number of bleeding sitesStannous FluorideSodium Monofluorophosphate
Number of Bleeding Sites at Week 445.44 ± 1.9268.30 ± 1.91
SecondaryBleeding Index (BI) at Week 4 and Week 12

BI was assessed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system to be used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed

Time frame:
Week 4, Week 12
Reported as:
Least squares mean · score on a scale
Bleeding Index (BI) at Week 4 and Week 12
score on a scaleStannous FluorideSodium Monofluorophosphate
BI at Week 4 (n=121, 122)0.29 ± 0.010.44 ± 0.01
BI at Week 12 (n=119, 119)0.27 ± 0.010.43 ± 0.01
SecondaryModified Gingival Index (MGI) at Week 4 and Week 12

MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration.

Time frame:
Week 4, Week 12
Reported as:
Least squares mean · score on a scale
Modified Gingival Index (MGI) at Week 4 and Week 12
score on a scaleStannous FluorideSodium Monofluorophosphate
MGI at Week 42.27 ± 0.012.40 ± 0.01
MGI at Week 122.29 ± 0.012.47 ± 0.01
SecondaryNumber of Participants With Visible Blood in Expectorate (Presence [Trace, Substantial]/Absence) at Week4 and Week 12

Visible blood in expectorate for each participant was classified as (i) Present (Trace or Substantial) (ii) Absent. The number of participants with blood 'Present' (Trace or Substantial) or 'absent' in expectorate was analyzed.

Time frame:
Week 4, Week 12
Reported as:
Number · number of participants
Number of Participants With Visible Blood in Expectorate (Presence [Trace, Substantial]/Absence) at Week4 and Week 12
number of participantsStannous FluorideSodium Monofluorophosphate
At Week 4, Visible blood= Present9289
At Week 4, Visible blood= Trace3531
At Week 4, Visible blood= Substantial5758
At Week 4, Visible blood= Absent3034
At Week 12, Visible blood= Present7278
At Week 12, Visible blood= Trace1813
At Week 12, Visible blood= Substantial5465
At Week 12, Visible blood= Absent4741

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stannous Fluoride—0/125 (0%)20/125 (16%)
Sodium Monofluorophosphate—0/128 (0%)22/128 (17.2%)
Most frequent other events
Most frequent other events
EventStannous FluorideSodium Monofluorophosphate
Oral hyperkeratosisGastrointestinal disorders15/12519/128
Gingival painGastrointestinal disorders2/1250/128
Gingival injuryInjury, poisoning and procedural complications1/1250/128
NasopharyngitisInfections and infestations1/1250/128
Oral herpesInfections and infestations1/1250/128
NauseaGastrointestinal disorders0/1251/128
Face InjuryInjury, poisoning and procedural complications0/1251/128
Head injuryInjury, poisoning and procedural complications0/1251/128
Neck injuryInjury, poisoning and procedural complications0/1251/128
Tooth fractureInjury, poisoning and procedural complications0/1251/128

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Stannous FluorideSodium MonofluorophosphateTotal
Mean39.39 ± 13.61036.37 ± 13.17937.86 ± 13.453
Sex: Female, Male
Sex: Female, Male(Participants)Stannous FluorideSodium MonofluorophosphateTotal
Female7173144
Male5455109
08

Study locations

1 site
  • GSK Investigational Site
    Las Vegas, Nevada 89146, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2015
First posted
Apr 26, 2016
Start
Nov 1, 2015
Primary completionActual
Mar 1, 2016
CompletionActual
Mar 4, 2016
Results first posted
Nov 11, 2016
Last update
Oct 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02750943
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 26, 2016
Start date
Nov 1, 2015
Primary completion
Mar 1, 2016
Completion
Mar 4, 2016
Results posted
Nov 11, 2016
Last update
Oct 26, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tin Fluorides

Start the discussion